The intravenous use of commercial disinfectants in the treatment of Novel Coronavirus (COVID-19): Unconventional, but is there evidence against it?
| Autor: | Edmund Leung, Adarsh P Shah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Intravenous drug business.industry Fibrosing alveolitis Disinfectant lcsh:R lcsh:Medicine covid intravenous drug users Intravenous use Oral ingestion Intravenous Drug User hypochlorite Medicine Risk of death General Agricultural and Biological Sciences business Intensive care medicine disinfectant |
| Zdroj: | Asian Journal of Medical Sciences, Vol 11, Iss 4, Pp 84-86 (2020) |
| ISSN: | 2467-9100 |
| Popis: | Background: On 24th April 2020, United States President Donald J Trump suggested the use of commercial surface disinfectants to treat patients infected with COVID-19 In his speech, President Trump also proposed medical research be conducted However, there are controversies regarding the toxicity of the disinfectant’s main ingredients sodium hypochlorite Aims and Objective: The purpose of this international collaborative study is to assess on feasibility and safety of disinfectants in human use Materials and Methods: Several safety labels of common commercialised brands of surface disinfectant from United Kingdom and New Zealand Furthermore, literature search was conducted through Pubmed on keywords keywords “sodium hypochlorite” AND “poisoning” AND “intravenous drug user” Result: All safety labels advised hazardous warning regarding irritation and caustic burns if ingested They all suggest water to wash out the effect if exposed to any mucus membrane such as eyes and broken skin No safety information was given by any of the brands against subcutaneous or intravenous injection No death in human was reported resulting from oral ingestion There were 2 case reports: one of blindness and one of fibrosing alveolitis resulting from ingestion during a domestic dispute Intravenous injection has only been seen in attempted murder cases or by intravenous drug users All the reported cases have resulted in 2 deaths, organ failures and venous thrombosis including pulmonary embolism Conclusion: There is no safety warning from the manufacturers of the studied surface disinfectants regarding intravenous use Intravenous injections in the literature suggests significant toxic outcome including death Randomised controlled trials on animals may be required to assess the risk of intravenous injection of surface disinfectants against the risk of death from COVID-19 infection [ABSTRACT FROM AUTHOR] Copyright of Asian Journal of Medical Sciences is the property of Manipal Colleges of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission However, users may print, download, or email articles for individual use This abstract may be abridged No warranty is given about the accuracy of the copy Users should refer to the original published version of the material for the full abstract (Copyright applies to all Abstracts ) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|